OncoRx (US) signs up Response Biomedical's white cell monitor
This article was originally published in Clinica
Executive Summary
OncoRx (US) will distribute and sell Response Biomedical's (Canada) point-of-care granulocyte monitor once it has been approved in North America. Under the deal, OncoRx will sell the hand-held monitor and associated disposables for oncology outpatient use in Canada and the US. Response will receive a $750,000 milestone payment when the device is approved by the FDA.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.